{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:11:44Z","timestamp":1788941504174,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"PA CURE","award":["4100088563"],"award-info":[{"award-number":["4100088563"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0582"],"award-info":[{"award-number":["W81XWH-22-1-0582"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01-CA255792-01A1"],"award-info":[{"award-number":["1R01-CA255792-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI\/NIH Cancer Center Support","award":["5P30CA056-036"],"award-info":[{"award-number":["5P30CA056-036"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This population-based study aimed to quantify fracture risk after androgen receptor pathway inhibitors in advanced prostate cancer patients by preexisting health conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were identified from the Surveillance, Epidemiology, and End Results\u2013Medicare files who received abiraterone acetate with prednisone or enzalutamide between January 1, 2013, and December 31, 2020. Health and fracture history were based on claims 1 year before androgen receptor pathway inhibitor with follow-up through December 31, 2020. The main outcome of the study was the cumulative fracture risk after first date of androgen receptor pathway inhibitor. Fine and Gray subdistribution hazard model was used to obtain adjusted relative risks with confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 10\u2009463 patients (6037 treated with abiraterone acetate with prednisone; 4426 treated with enzalutamide). The 3-year fracture risk after androgen receptor pathway inhibitor was high, exceeding 25% among those without a prior fracture. Among 1445 men with a fracture the year before androgen receptor pathway inhibitor, 3-year fracture risk exceeded 50% and remained high (above 44%) despite using bone health agents. A recent history of fracture was associated with a 2.84-fold fracture risk (adjusted hazard ratio [HR] = 2.84, 95% confidence interval [CI] = 2.58 to 3.12). Preexisting osteoporosis and a comorbidity score of 2 or higher were associated with 15% (adjusted HR = 1.15, 95% CI = 1.03 to 1.29) and 11% (adjusted HR = 1.11, 95% CI = 1.00 to 1.24) higher fracture risks. Bone health agent use was associated with a 23% lower fracture risk (adjusted HR = 0.77, 95% CI = 0.70 to 0.83).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fracture risk after androgen receptor pathway inhibitor was high, exceeding 44% within 3\u2009years in those with prior fractures despite bone health agents, suggesting limited benefit in patients with poor bone quality. Early identification and intervention for patients at high risk of fractures are critical.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag061","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:34:28Z","timestamp":1772541268000},"page":"1290-1298","source":"Crossref","is-referenced-by-count":1,"title":["Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-7737","authenticated-orcid":false,"given":"Grace","family":"Lu-Yao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"College of Population Health, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-9772","authenticated-orcid":false,"given":"Nikita","family":"Nikita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-1151","authenticated-orcid":false,"given":"Scott W","family":"Keith","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7697-0403","authenticated-orcid":false,"given":"Krupa","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0263-8708","authenticated-orcid":false,"given":"Amy L","family":"Shaver","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-6184","authenticated-orcid":false,"given":"Swapnil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Steinbock-Malfer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hushan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-6926","authenticated-orcid":false,"given":"Christopher","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Drexel University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-2317","authenticated-orcid":false,"given":"Kevin K","family":"Zarrabi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J","family":"Freedland","sequence":"additional","affiliation":[{"name":"Department of Urology, Cedars-Sinai Medical Center , Los Angeles, CA,","place":["United States"]},{"name":"Urology Section, Durham VA Medical Center , Durham, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-672X","authenticated-orcid":false,"given":"William K","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]},{"name":"Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"2026070708471674200_djag061-B1","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"2026070708471674200_djag061-B2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"2026070708471674200_djag061-B3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026070708471674200_djag061-B4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"New Engl J Med"},{"key":"2026070708471674200_djag061-B5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026070708471674200_djag061-B6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New Engl J Med"},{"key":"2026070708471674200_djag061-B7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"New Engl J Med"},{"key":"2026070708471674200_djag061-B8","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"New Engl J Med"},{"key":"2026070708471674200_djag061-B9","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026070708471674200_djag061-B10","doi-asserted-by":"crossref","first-page":"e2031730-e2031730","DOI":"10.1001\/jamanetworkopen.2020.31730","article-title":"Assessment of a clinical trial\u2013derived survival model in patients with metastatic castration-resistant prostate cancer","volume":"4","author":"Coquet","year":"2021","journal-title":"JAMA Network Open"},{"key":"2026070708471674200_djag061-B11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit Med"},{"key":"2026070708471674200_djag061-B12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"New Engl J Med"},{"key":"2026070708471674200_djag061-B13","doi-asserted-by":"publisher","first-page":"S956","DOI":"10.1016\/j.annonc.2023.09.2717","article-title":"1767MO External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)\/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials","volume":"34","author":"Parker","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070708471674200_djag061-B14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"2026070708471674200_djag061-B15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070708471674200_djag061-B16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.steroids.2008.10.003","article-title":"Androgens and bone","volume":"74","author":"Clarke","year":"2009","journal-title":"Steroids"},{"key":"2026070708471674200_djag061-B17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2147\/CIA.S115472","article-title":"A concise review of testosterone and bone health","volume":"11","author":"Mohamad","year":"2016","journal-title":"Clin Interv Aging"},{"key":"2026070708471674200_djag061-B18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/gerona\/gls068","article-title":"The role of androgens and estrogens on healthy aging and longevity","volume":"67","author":"Horstman","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026070708471674200_djag061-B19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","article-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men","volume":"184","author":"Alibhai","year":"2010","journal-title":"J Urol"},{"key":"2026070708471674200_djag061-B20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States","volume":"21","author":"Beebe-Dimmer","year":"2012","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026070708471674200_djag061-B21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Med J Aust"},{"key":"2026070708471674200_djag061-B22","article-title":"SEER-Medicare Linked Data Resource","author":"National Cancer Institute Division of Cancer Control & Population Sciences","year":"2023"},{"key":"2026070708471674200_djag061-B23","article-title":"Number of Persons by Race and Hispanic Ethnicity for SEER Participants (2020 Census Data)","author":"Surveillance Epidemiology and End Results (SEER) Program"},{"key":"2026070708471674200_djag061-B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jncimonographs\/lgz029","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026070708471674200_djag061-B25","first-page":"49","article-title":"What Medicare has meant to older Americans","volume":"18","author":"Moon","year":"1996","journal-title":"Health Care Financ Rev."},{"key":"2026070708471674200_djag061-B26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.4930","article-title":"Denosumab and mortality in a real-world setting: a comparative study","volume":"38","author":"Alarkawi","year":"2023","journal-title":"J Bone Miner Res"},{"key":"2026070708471674200_djag061-B27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","article-title":"Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Jones","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026070708471674200_djag061-B28","doi-asserted-by":"publisher","first-page":"e2025826","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026070708471674200_djag061-B29","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1038\/s41598-023-32776-1","article-title":"Racial and ethnic difference in the risk of fractures in the United States: a systematic review and meta-analysis","volume":"13","author":"Bao","year":"2023","journal-title":"Sci Rep"},{"key":"2026070708471674200_djag061-B30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/aja.2011.104","article-title":"Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy","volume":"14","author":"Storer","year":"2012","journal-title":"Asian J Androl"},{"key":"2026070708471674200_djag061-B31","doi-asserted-by":"publisher","first-page":"109306","DOI":"10.1016\/j.steroids.2023.109306","article-title":"An overview on androgen-mediated actions in skeletal muscle and adipose tissue","volume":"199","author":"Rizk","year":"2023","journal-title":"Steroids."},{"key":"2026070708471674200_djag061-B32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/pcan.2009.50","article-title":"Bone health and prostate cancer","volume":"13","author":"Saylor","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070708471674200_djag061-B33","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","article-title":"Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group","volume":"25","author":"Brown","year":"2020","journal-title":"J Bone Oncol"},{"key":"2026070708471674200_djag061-B34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1799-7","article-title":"Fracture risk in patients with prostate cancer on androgen deprivation therapy","volume":"16","author":"L\u00f3pez","year":"2005","journal-title":"Osteoporosis Int"},{"key":"2026070708471674200_djag061-B35","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2967\/jnumed.124.267526","article-title":"Brain metabolic correlates of the off-target effects of enzalutamide on the central nervous system of patients with advanced prostate cancer","volume":"65","author":"Bauckneht","year":"2024","journal-title":"J Nucl Med"},{"key":"2026070708471674200_djag061-B36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","article-title":"Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302","volume":"68","author":"Saad","year":"2015","journal-title":"Eur Urol"},{"key":"2026070708471674200_djag061-B37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctrv.2018.04.014","article-title":"The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer","volume":"68","author":"Saad","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2026070708471674200_djag061-B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","article-title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis","volume-title":"J Clin Oncol.","author":"Tombal","year":"2019"},{"key":"2026070708471674200_djag061-B39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"2026070708471674200_djag061-B40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers"},{"key":"2026070708471674200_djag061-B41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"2026070708471674200_djag061-B42","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070708471674200_djag061-B43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2026070708471674200_djag061-B44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10198-015-0716-7","article-title":"Health resource utilization associated with skeletal-related events: results from a retrospective European study","volume":"17","author":"Body","year":"2016","journal-title":"Eur J Health Econ"},{"key":"2026070708471674200_djag061-B45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"New Engl J Med"},{"key":"2026070708471674200_djag061-B46","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070708471674200_djag061-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"2026070708471674200_djag061-B48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.27830","article-title":"Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy","volume":"119","author":"Morgans","year":"2013","journal-title":"Cancer"},{"key":"2026070708471674200_djag061-B49","article-title":"Urology Research: DEXA scans in patients receiving ADT for prostate cancer","author":"Verana Health","year":"2025"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag061\/67273386\/djag061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1290\/67273386\/djag061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1290\/67273386\/djag061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:49:54Z","timestamp":1783428594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/7\/1290\/8510731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,7]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag061","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,7]]}}}